BR112013003579A2 - adenovírus, células, e, métodos para tratar câncer - Google Patents
adenovírus, células, e, métodos para tratar câncerInfo
- Publication number
- BR112013003579A2 BR112013003579A2 BR112013003579A BR112013003579A BR112013003579A2 BR 112013003579 A2 BR112013003579 A2 BR 112013003579A2 BR 112013003579 A BR112013003579 A BR 112013003579A BR 112013003579 A BR112013003579 A BR 112013003579A BR 112013003579 A2 BR112013003579 A2 BR 112013003579A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- adenovirus
- cells
- treat cancer
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
- C12N5/068—Stem cells; Progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37421510P | 2010-08-16 | 2010-08-16 | |
| PCT/US2011/048005 WO2012024350A2 (en) | 2010-08-16 | 2011-08-16 | Anti-cancer adenoviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013003579A2 true BR112013003579A2 (pt) | 2016-06-07 |
Family
ID=45605646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013003579A BR112013003579A2 (pt) | 2010-08-16 | 2011-08-16 | adenovírus, células, e, métodos para tratar câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9187733B2 (enExample) |
| EP (1) | EP2606137B1 (enExample) |
| JP (1) | JP5905460B2 (enExample) |
| KR (1) | KR101667094B1 (enExample) |
| CN (1) | CN103180448B (enExample) |
| AU (1) | AU2011292119B2 (enExample) |
| BR (1) | BR112013003579A2 (enExample) |
| CA (1) | CA2807778C (enExample) |
| SG (1) | SG187785A1 (enExample) |
| WO (1) | WO2012024350A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013003579A2 (pt) * | 2010-08-16 | 2016-06-07 | Salk Inst For Biological Studi | adenovírus, células, e, métodos para tratar câncer |
| CA2867129C (en) * | 2012-03-13 | 2023-11-21 | Salk Institute For Biological Studies | Selective cell targeting using adenovirus and chemical dimers |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| ES2837400T3 (es) | 2015-10-05 | 2021-06-30 | Salk Inst For Biological Studi | Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| MX2021014525A (es) * | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA137094A (en) | 1911-08-31 | 1911-11-28 | Sheppe, Alice L. | Cloth measuring and price calculating machine |
| FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| DK1199368T3 (da) * | 1998-07-07 | 2004-04-13 | Transgene Sa | Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse |
| EP1083229A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
| EP1284294A4 (en) * | 2000-05-26 | 2004-10-13 | Sumitomo Pharma | RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01) |
| US20020106382A1 (en) * | 2000-07-14 | 2002-08-08 | Young Charles S.H. | Modified adenovirus and uses thereof |
| US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| WO2003092579A2 (en) | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
| US20060099709A1 (en) | 2002-10-01 | 2006-05-11 | Chuan-Yuan Li | Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors |
| WO2005048950A2 (en) | 2003-11-17 | 2005-06-02 | Biomune, Inc. | Tumor and infectious disease therapeutic compositions |
| EP2352516A2 (en) * | 2008-09-26 | 2011-08-10 | Auburn University | Immunization of avians by mucosal administration of non-replicating vectored vaccines |
| BR112013003579A2 (pt) * | 2010-08-16 | 2016-06-07 | Salk Inst For Biological Studi | adenovírus, células, e, métodos para tratar câncer |
-
2011
- 2011-08-16 BR BR112013003579A patent/BR112013003579A2/pt not_active Application Discontinuation
- 2011-08-16 AU AU2011292119A patent/AU2011292119B2/en active Active
- 2011-08-16 CN CN201180050032.7A patent/CN103180448B/zh active Active
- 2011-08-16 EP EP11818698.0A patent/EP2606137B1/en active Active
- 2011-08-16 JP JP2013524945A patent/JP5905460B2/ja active Active
- 2011-08-16 WO PCT/US2011/048005 patent/WO2012024350A2/en not_active Ceased
- 2011-08-16 CA CA2807778A patent/CA2807778C/en active Active
- 2011-08-16 KR KR1020137006526A patent/KR101667094B1/ko active Active
- 2011-08-16 SG SG2013009790A patent/SG187785A1/en unknown
-
2013
- 2013-02-15 US US13/768,933 patent/US9187733B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012024350A3 (en) | 2012-07-05 |
| US20130243729A1 (en) | 2013-09-19 |
| SG187785A1 (en) | 2013-03-28 |
| EP2606137A2 (en) | 2013-06-26 |
| EP2606137B1 (en) | 2018-08-01 |
| US9187733B2 (en) | 2015-11-17 |
| KR101667094B1 (ko) | 2016-10-17 |
| CA2807778C (en) | 2017-03-07 |
| JP2013537426A (ja) | 2013-10-03 |
| JP5905460B2 (ja) | 2016-04-20 |
| WO2012024350A2 (en) | 2012-02-23 |
| CA2807778A1 (en) | 2012-02-23 |
| AU2011292119B2 (en) | 2015-06-11 |
| CN103180448A (zh) | 2013-06-26 |
| CN103180448B (zh) | 2017-04-12 |
| EP2606137A4 (en) | 2014-01-08 |
| AU2011292119A1 (en) | 2013-02-28 |
| KR20130126590A (ko) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013003579A2 (pt) | adenovírus, células, e, métodos para tratar câncer | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| CY1121038T1 (el) | Θεραπεια καρκινου μαστου | |
| BR112013010569A2 (pt) | moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| HUE049886T2 (hu) | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| BR112013001122A2 (pt) | composições ativas terapêuticas e seu método de uso | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
| EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
| BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
| MX2012011718A (es) | Anticuerpos anti-erbb3. | |
| EA201291194A1 (ru) | Индолы | |
| EA201290901A1 (ru) | Фитоканнабиноиды для лечения злокачественной опухоли | |
| PT3214091T (pt) | Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| EA201201000A1 (ru) | Способы лечения колоректального рака | |
| CL2011002784A1 (es) | Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo. | |
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| EP4582090A3 (en) | Composition comprising pegylated arginine deiminase | |
| BR112013014076A2 (pt) | métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |